TherapeuticsMD, Inc. (TXMD)

Over the past six months, TherapeuticsMD's stock price has experienced fluctuations, with a notable increase of 41.8% over the past 12 months. Key events impacting the stock price include the Third Quarter 2025 Financial Results announcement on November 12, 2025, which led to a -3.57% change in stock price, and the Full Year 2025 Financial Results announcement on March 30, 2026, which saw a +1.51% change. A Schedule 13G filing indicated a passive investment disclosure on April 6, 2026. The stock experienced volatility in mid-April 2026. The First Quarter 2025 Financial Results announcement on May 13, 2025, resulted in a -3.95% change, while the Second Quarter 2025 Financial Results announcement on August 12, 2025, saw a +4.98% change. The stock has shown a general downtrend starting from March 25, 2026, with a total price change of -11.35% during this period.

Specific information regarding the demand seasonality for TherapeuticsMD, Inc.'s products is not explicitly detailed. A seasonality analysis of TXMD's historical stock price data suggests that May may not be an ideal month to invest, with only a 30.00% probability of a positive return, while January has historically offered the highest probability of positive returns at 60.00%. Pharmaceutical products might experience relatively stable demand throughout the year, though factors like insurance cycles or healthcare spending trends could introduce some variability.

TherapeuticsMD, Inc. is a pharmaceutical royalty company focused on women's healthcare, licensing its intellectual property to third-party pharmaceutical companies and generating revenue through royalties and milestone payments. The company's major products, licensed to Mayne Pharma, address various stages of women's health, including IMVEXXY for dyspareunia, BIJUVA for vasomotor symptoms, ANNOVERA as a contraceptive vaginal system, and prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names.

TherapeuticsMD, Inc. primarily operates in the United States, selling its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors across the country. Its headquarters are located in Boca Raton, Florida.

Information specifically detailing TherapeuticsMD's brand reputation in the past year is not readily available. Analyst sentiment on TXMD stock is often mixed, reflecting the high-risk nature of small-cap biotech companies. TherapeuticsMD has received a consensus rating of "Sell" from analysts, based on one research report in the past 90 days. Its MarketRank™ score indicates it scored higher than only 2% of companies evaluated by MarketBeat in the medical sector.

TherapeuticsMD, Inc. has a mixed ownership structure, including institutional, insider, and retail investors. Major institutional owners include Rubric Capital Management LP, Clearline Capital LP, and Vanguard Group Inc. Key individual shareholders include Brian Bernick, Robert G. Finizio, and John Ck Milligan Iv. Retail investors also hold a significant portion of the stock.